clinical trial · NCT05024552
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
H. Lee Moffitt Cancer Center and Research Institute·phase1·recruiting·n = 22
Acute Myeloid Leukemia With FLT3/ITD MutationGilteritinibVyxeos
brief summary
This study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy. Those patients entering a complete remission or a complete remission with incomplete blood count recovery will be allowed to proceed to consolidation therapy with vyxeos and gilteritinib. Those patients who do not proceed to an allogeneic stem cell transplant for any reason are able to enter the maintenance phase of this trial using daily gilteritinib
started
Feb 25, 2022
primary completion
Feb 15, 2027
completion
Mar 1, 2027
last updated
Dec 5, 2025
official title
A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol